Glaukos (NYSE:GKOS) Stock, Quote.Headers.trade-ideas

Glaukos

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Biotech

Earnings

News

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

GKOS

TNDM

Boston Scientific Corporation (NYSE: BSX) is scheduled to report second-quarter 2024 results on Jul 24, before the opening bell.

Will WATCHMAN Sales Aid Boston Scientific&#39;s Q2 Earnings?

visa shutter2

Downgrades

HELE

SPOT

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Glaukos Corporation (NYSE: GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.

Here&#39;s Why You Should Retain Glaukos Stock for Now

Glaukos Corp

Boston Scientific Corporation&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>) is scheduled to report second-quarter 2024 results on Jul 24, before the opening bell.
In the last reported quarter, the company&#39;s earnings per share of 56 cents exceeded the Zacks Consensus Estimate by 9.8%. BSX&#39;s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.49%, on average.
<h3>Q2 Estimates</h3>
The Zacks Consensus Estimate for second-quarter total revenues is pegged at $4.02 billion, suggesting an improvement of 11.7% from the prior-year quarter&#39;s reported number.
The consensus mark for adjusted earnings stands at 58 cents per share, implying a 9.4% rise from the year-ago quarter&#39;s reported figure.
For the second quarter of 2024, the company projected revenue growth in the range of approximately 10.5-12.5% on a reported basis (an increase of 10-12% organically). Adjusted earnings are expected in the range of 57-59 cents per share.
<h3>Estimate Revision Trend Ahead of Earnings</h3>
The Zacks Consensus Estimate for Boston Scientific&#39;s second-quarter earnings has remained unchanged at 58 cents per share in the past 60 days.
Let&#39;s briefly look at how things have progressed for the MedTech major leading up to this announcement.
<h3>Factors at Play</h3>
With U.S. hospital visits being on the rise through the second-quarter months of 2024, Boston Scientific, with its innovative pipeline, expansion into faster growth markets, globalization efforts and enhanced digital capabilities, looks well-positioned to report decent sales results for this period.
However, the rate of growth is expected to have remained sluggish amid a challenging supply environment in limited geographies. Further, the business is expected to have faced the hurdle of surging labor and raw material costs, as well as healthcare staffing shortages, which might have weighed on the bottom line in the second quarter.
On a geographic basis, despite all macroeconomic headwinds, the company registered strong growth in every geographic region in the last reported quarter, with core business units gaining or maintaining market share. However, with global staffing issues and the supply chain issue still remaining prominent, the international business of BSX is once again expected to have been partially hurt in the second quarter.
The company is expected to have registered strong growth in the Asia Pacific, led by strength in China and Japan. Growth in Japan is expected to have been fueled by new products, most notably AGENT drug-coated balloon (DCB), Rezum, Access solutions products, POLARx FIT and WATCHMAN FLX. Performance in China is expected to have been led by the company&#39;s advanced portfolio, with particular strength in its interventional cardiology therapies, WATCHMAN, CRM and PI business units.
<div class="chart_embed">
<h3>Boston Scientific Corporation Price and EPS Surprise</h3>
<img alt="Boston Scientific Corporation Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/a5/1721134654.png" style="height:263px; width:538px" title="" />
Boston Scientific Corporation price-eps-surprise | Boston Scientific Corporation Quote
</div>
In EMEA, the company is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies, as well as endoscopy, urology and electrophysiology divisions, fueled by ongoing investments in emerging markets, new and ongoing product launches across the portfolio, pricing discipline and strong commercial execution. The company is expected to have witnessed strength in ACURATE Neo2 and FARAPULSE.
The WATCHMAN subsegment within the Cardiovascular division has shown meaningful strength in recent times. It is once again expected to report strong growth in the to-be-reported quarter on sustained momentum from second-generation WATCHMAN FLX, ongoing clinical evidence, globalization and commercial execution. With the full launch of WATCHMAN FLX Pro in the United States along with the recent launch of the same in Japan and Canada, this momentum is expected to have continued within the WATCHMAN franchise in the second quarter.
The consensus estimate for WATCHMAN revenues is pegged at $373.7 million for the second quarter, indicating a 17.9% improvement from the year-ago period.
The Interventional Cardiology business is expected to have registered year-over-year growth in the Coronary Therapies franchise, led by sales in the imaging portfolio and AGENTDCB in Japan. The ongoing launch of AVVIGO+, the company&#39;s AI-guided imaging platform, is also likely to have contributed to the top line. Further, following the FDA approval of AGENT DCB in the first quarter, the company planned for a limited launch in the second quarter. This, too, might have contributed to top-line growth in the second quarter. However, this might have been offset by the ongoing price pressure on drug-eluting stents.
Structural Heart Valves, Complex PCI and Imaging franchises are expected to have recorded strong growth backed by solid European performance, courtesy of the ACURATE neo2 TAVR platform.
The consensus estimate for Interventional Cardiology revenues of $663.7 million projects a 5.5% improvement in the second quarter.
Within the Peripheral Interventions business, second-quarter sales are expected to have been driven by the strong performance of the drug-eluting franchise, supported by ongoing clinical evidence and the company&#39;s category leadership portfolio. Specifically, Arterial franchise revenues are expected to have been strong. Within Venous, the company might have once again witnessed strong sales from Varithena and Clot Management.
Peripheral Interventions revenues are estimated at $584.2 million, implying an improvement of 9.2% in the second quarter.
Interventional Oncology is expected to have gained from strong momentum in the company&#39;s advanced cancer therapies, TheraSphere and ICEfx, as well as the robust set of embolization access and delivery tools. Recently, the company launched its EMBOLD Soft and Packing Coils, which, along with the EMBOLD fibroid coil, complete its detachable coil system.
Within Urology/ Pelvic Health, Stone Management, Prostate Health and Pelvic Health franchises are expected to have recorded strong growth, banking on strong performances of LithoVue and Rezum in key countries.
Within Endoscopy, broad-based recovery across regions and growing strength in infection prevention are expected to have driven second-quarter revenues. The company is expected to report strong momentum in the AXIOS stent and single-use imaging franchise. The growth momentum is expected to have continued with the recent U.S. marketing authorization for an expanded indication of AXIOS to include gallbladder drainage, increasing access to more patients with this platform.
Further, following the CE Mark for the MANTIS Clip, the National Institute for Health and Care Excellence&nbsp;in the UK issued positive guidance for the endoscopic bariatric surgery procedure. This is expected to have boosted sales of the company&#39;s endoluminal surgery franchise.
Within Neuromodulation, the company is likely to have registered balanced growth across the Vercise Genus portfolio and the innovative Image Guided Programming, which is designed to improve the precision and efficiency of the deep brain stimulation procedure.
<h3>What Our Quantitative Model Predicts</h3>
Per our proven model, a stock with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates. This is not the case, as you can see below.
Earnings ESP: Boston Scientific has an Earnings ESP of -1.72%.
Zacks Rank: Boston Scientific carries a Zacks Rank #3 currently.
<h3>Stocks to Consider</h3>
Here are a few medical stocks worth considering, as these have the right combination of elements to post an earnings beat this quarter.
National Vision (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eye#NASDAQ">EYE</a>) has an Earnings ESP of +193.33% and a Zacks Rank #2.
The company is expected to release second-quarter 2024 results soon. National Vision&#39;s earnings are expected to decline 17.2% in 2024. National Vision surpassed earnings in each of the trailing four quarters, the average being 62.06%.
Glaukos (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) has an Earnings ESP of +12.53% and a Zacks Rank #2. The company is due to release second-quarter 2024 results on Jul 31.
Glaukos has an expected earnings growth of 1.3% for 2024. Glaukos is expected to witness revenue growth of 15.1% in 2024.
Tandem Diabetes Care (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tndm#NASDAQ">TNDM</a>) has an Earnings ESP of +23.54% and a Zacks Rank of 3 at present. The company is scheduled to release its second-quarter 2024 results on Aug 1.
Tandem Diabetes has an expected revenue growth of 15.8% for 2024. Tandem Diabetes has a trailing four-quarter average earnings surprise of 9.92%.
<a href="https://www.zacks.com/stock/news/2302708/will-watchman-sales-aid-boston-scientific-s-bsx-q2-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-2302708">To read this article on Zacks.com click here.</a>

Will WATCHMAN Sales Aid Boston Scientific's Q2 Earnings?

Truist Securities analyst Samuel Brodovsky maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $125 to $141.

Price Target

Truist Securities Maintains Buy on Glaukos, Raises Price Target to $141

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $112 to $131.

BTIG Maintains Buy on Glaukos, Raises Price Target to $131

Morgan Stanley analyst Patrick Wood maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Equal-Weight and raises the price target from $100 to $120.

Morgan Stanley Maintains Equal-Weight on Glaukos, Raises Price Target to $120

During the last three months, 10 analysts shared their evaluations of Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $120.7, a high estimate of $132.00, and a low estimate of $110.00. Surpassing the previous average price target of $110.00, the current average has increased by 9.73%.
<img src="https://www.benzinga.com/files/images/story/2024/1720641615_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Glaukos by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Sarcone</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Allen Gong</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$108.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Glaukos's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Glaukos's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>Discovering Glaukos: A Closer Look</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Glaukos: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Glaukos's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 15.86%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Glaukos's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -47.7%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Glaukos's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -8.95%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Glaukos's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.85, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Glaukos

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Redburn Atlantic analyst Agnieszka Pustula downgraded the rating for Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) from Neutral to Sell and announced a price target of $230. Spotify shares fell 0.7% to close at $311.55 on Tuesday. <a href="https://www.benzinga.com/quote/SPOT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities analyst Jason Kupferberg downgraded Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) from Buy to Neutral, while cutting the price target from $305 to $297. Visa shares fell 0.4% to close at $265.44 on Tuesday. <a href="https://www.benzinga.com/quote/V/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Linda Bolton Weiser downgraded the rating for Helen of Troy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) from Buy to Neutral, while lowering the price target from $139 to $67. Helen Of Troy shares dipped 27.7% to close at $64.33 on Tuesday. <a href="https://www.benzinga.com/quote/HELE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Ella Smith downgraded LegalZoom.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) from Overweight to Neutral and lowered the price target from $14 to $9. LegalZoom shares fell 1.5% to settle at $7.85 on Tuesday. <a href="https://www.benzinga.com/quote/LZ/analyst-ratings">See how other analysts view this stock. See how other analysts view this stock.</a></li>
<li>Citigroup analyst Joanne Wuensch downgraded the rating for Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Buy to Neutral, while raising the price target from $130 to $132. Glaukos shares fell 0.7% to close at $121.75 on Tuesday. <a href="https://www.benzinga.com/quote/GKOS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39690602/delta-air-lines-likely-to-report-lower-q2-earnings-here-are-the-recent-forecast-changes-from-wall-s">Delta Air Lines Likely To Report Lower Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Citigroup analyst Joanne Wuensch downgrades Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Buy to Neutral and raises the price target from $130 to $132.

Citigroup Downgrades Glaukos to Neutral, Raises Price Target to $132

Glaukos Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry&#39;s 5.4% growth. The S&amp;P 500 Index has also increased 15% in the same time frame.
Glaukos, with a market capitalization of $5.91 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 1.3% for 2024, followed by 43.1% growth in 2025, and expects to maintain its strong performance in terms of revenues as well.
The company has a trailing four-quarter average negative earnings surprise of 4.74%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/72/70164.jpg?v=1990519273" /> 
Image Source: Zacks Investment Research
<h3>Key Catalysts</h3>
In 2023, Glaukos witnessed sales returning to growth after experiencing a downturn in 2022. This positive shift can be attributed to a more favorable macroeconomic climate and the introduction of a series of new products in recent quarters. The first-quarter results also reflected the strength. The company anticipates sustained robust demand in its international Glaucoma and Corneal Health product lines to support its top-line growth in the rest of 2024.
The commercial launch of the iStent infinite in 2023 has provided a significant lift to the U.S. glaucoma franchise, positioning it as a key growth catalyst in the forthcoming quarters. The company&#39;s optimistic revenue projections for 2024 indicate a positive trajectory.
Meanwhile, the new local coverage determinations, proposed in June 2023, are likely to remove certain ophthalmic goniotomy and canaloplasty procedures from coverage. This is also expected to have a positive impact on the iStent business in 2024.
Over recent quarters, GKOS has launched a suite of products, including iPrime, iAccess and iStent, which have been instrumental in boosting the company&#39;s revenues. In December, the company achieved a milestone by securing FDA approval for its latest product, iDose TR, to lower intraocular pressure in individuals with ocular hypertension or open-angle glaucoma.
These innovations are expected to continue to bolster Glaukos&#39; growth trajectory into 2024. Earlier this month, the company received a permanent Healthcare Common Procedure Coding System J-code from the U.S. Centers for Medicare and Medicaid Services that should drive patient access in the United States. This is because it will likely accelerate the billing and physician reimbursement procedures.
In May, Glaukos announced first-quarter 2024 results. The company&#39;s net sales were $85.6 million, up 16% year over year. Revenues for 2024 are estimated to be in the range of $357-$365 million, implying a year-over-year improvement of 13.4-16%.
<h3>What&#39;s Hurting GKOS?</h3>
Although Glaukos has a promising pipeline, it has faced setbacks in terms of clinical development or regulatory activities. Any potential clinical or regulatory setback can have an adverse impact on the company&#39;s share price, thereby hurting investors&#39; wealth.
The FDA denied approval to a pre-market approval application for the ab-externo device for glaucoma, MicroShunt. The company is currently evaluating alternate regulatory pathways for approval, and its commercial launch in the United States remains uncertain.
Moreover, Glaukos currently relies on a limited number of third-party suppliers, in some cases sole suppliers, to supply components for the iStent, the iStent inject models and other pipeline products. If one or more of these suppliers cease to provide the company with sufficient quantities of components or drugs in a timely manner or on acceptable terms, it would have to seek alternative sources of supply.
Glaukos&#39; production of the iStent, iStent inject models and other products in development depends on a select group of third-party suppliers, occasionally exclusive ones. If any of these suppliers fail to deliver the necessary components or drugs in a timely manner or on acceptable terms, Glaukos would be compelled to find other suppliers to maintain its production line.
<h3>Estimate Trend</h3>
The bottom-line estimate for GKOS is pegged at a loss of $2.24 per share for 2024, which narrowed 2 cents in the past 30 days. The Zacks Consensus Estimate for 2024 revenues is pinned at $362.3 million, indicating growth of 15.1% from the top line recorded in 2023.
<h3>Stocks to Consider</h3>
Some better-ranked stocks in the broader medical space that have announced quarterly results are&nbsp;DaVita&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>),&nbsp;Ecolab&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>) and&nbsp;Universal Health Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>).
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 29.4%.
DaVita&#39;s shares have risen 32.1% compared with the&nbsp;industry&#39;s 5% growth so far this year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%.
Ecolab&#39;s shares have rallied 18.8% against the&nbsp;industry&#39;s 21.9% decline so far this year.
Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank #2 at present. UHS has an estimated earnings growth rate of 30.5% for 2024.
UHS&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. The company&#39;s shares have rallied 21.2% compared to the&nbsp;industry&#39;s 18.5% increase so far this year.
<a href="https://www.zacks.com/stock/news/2296487/here-s-why-you-should-retain-glaukos-gkos-stock-for-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2296487">To read this article on Zacks.com click here.</a>

Here's Why You Should Retain Glaukos Stock for Now

Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the &quot;Exchange Agreements&quot;) with certain holders of its&nbsp;2.75%&nbsp;Convertible Senior Notes due 2027 (the &quot;Existing Convertible Notes&quot;). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of&nbsp;$230 million&nbsp;principal amount of Existing Convertible Notes for aggregate consideration consisting of a number of shares of the company&#39;s common stock, par value&nbsp;$0.001&nbsp;per share (the &quot;Common Stock&quot;), to be determined over an averaging period commencing on June 14, 2024, and cash in lieu of fractional shares and in respect of accrued interest on the Existing Convertible Notes. These exchange transactions are expected to close on or about June 25, 2024, subject to the satisfaction of customary closing conditions.

Glaukos Corporation Reveals Agreements To Exchange $230M In Principal Amount Of Its 2.75% Convertible Senior Notes Due 2027 For Common Stock; These Exchange Transactions Are Expected To Close On Or About June 25, 2024

Stifel analyst Thomas Stephan maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $110 to $130.

Stifel Maintains Buy on Glaukos, Raises Price Target to $130

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $110 to $120.

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $120

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $114.58, a high estimate of $130.00, and a low estimate of $100.00. Witnessing a positive shift, the current average has risen by 8.92% from the previous average price target of $105.20.
<img src="https://www.benzinga.com/files/images/story/2024/1716400872_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Glaukos is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Sarcone</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Allen Gong</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Glaukos's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Glaukos's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>Discovering Glaukos: A Closer Look</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Understanding the Numbers: Glaukos's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Glaukos's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 15.86%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -47.7%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -8.95%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Glaukos's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.36%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.85, Glaukos faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $120 to $130.

Citigroup Maintains Buy on Glaukos, Raises Price Target to $130

Jefferies analyst Michael Sarcone upgrades Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Hold to Buy and raises the price target from $84 to $125.

Upgrades

Jefferies Upgrades Glaukos to Buy, Raises Price Target to $125

Thursday,&nbsp;Glaukos Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported a first-quarter adjusted EPS loss of $(0.70), up from $(0.59) a year ago, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $(0.57)</a>.
The company reported sales of $85.6 million, up 16% Y/Y, beating the consensus of $79.6 million.
Guidance:&nbsp;Glaukos expects 2024 sales of $357 million-$365 million, compared to the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38564015/glaukos-announces-first-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $357.934 million</a>.
William Blair reports that iDose exceeded expectations during its initial&nbsp;quarter of launch,&nbsp;with the iStent franchise experiencing growth in the mid-teens, surpassing expectations as well.&nbsp;The&nbsp;growth&nbsp;was driven&nbsp;by the demand for the iStent&nbsp;infinite&nbsp;product, which&nbsp;not only&nbsp;contributed to market expansion&nbsp;but also&nbsp;captured market share in the core combo-cataract segment.&nbsp;
&#8220;Clearly,&nbsp;the glaucoma business is firing on all cylinders, and with iDose access set to improve in the second quarter and beyond, the outlook remains quite positive,&#8221; William Blair analyst said.
Throughout the first half of 2024, Glaukos has achieved significant reimbursement and commercial milestones.&nbsp;
With the full launch of iDose expected to commence, the company anticipates experiencing substantial growth in the latter half of the year.&nbsp;
Analysts suggest that as Glaukos is likely to shift its focus from surgical MIGS to a broader range of ophthalmic solutions, establishing itself as a hybrid pharma/device powerhouse, &#8220;investor interest should continue to gain momentum,&#8221; the analyst writes.
William Blair&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/GKOS/analyst-ratings" rel="noreferrer noopener">rates the stock Outperform</a>.
Other analyst reactions:
<ul>
<li>BTIG maintains Buy on Glaukos, with a price target of $112, up from $107.</li>
<li>JP Morgan maintains Glaukos with an Overweight rating&nbsp;and raises&nbsp;the price target from&nbsp;$108&nbsp;to&nbsp;$110.</li>
<li>Wells Fargo maintains Glaukos with an Overweight rating&nbsp;with&nbsp;a higher price target of $110, up from $103.</li>
<li>Needham, too, maintains with a Buy and raises the price target from&nbsp;$108&nbsp;to&nbsp;$113.</li>
<li>Truist Securities reiterates Glaukos with a Buy and raises the price target from&nbsp;$120&nbsp;to&nbsp;$125.</li>
</ul>
Price Action: GKOS shares are up 6.69% at $105.53 at last check Thursday.
Photo by Amanda Dalbjörn on Unsplash

Analyst Color

Equities

Guidance

Health Care

Reiteration

Movers

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $107 to $112.

BTIG Maintains Buy on Glaukos, Raises Price Target to $112

JP Morgan analyst Allen Gong maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $108 to $110.

JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $110

WIIM

Glaukos shares are trading higher after the company reported better-than-expected Q1 sales results and issued FY24 net sales guidance above estimates. Also, multiple firms raised their respective price targets on the stock.

U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) rose sharply during Thursday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/CHRW/earnings">first-quarter financial results</a>.
C.H. Robinson Worldwide posted adjusted earnings of 86 cents per share, beating market estimates of 82 cents per share. The company's quarterly sales came in at $4.412 billion versus expectations of $4.269 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
C.H. Robinson Worldwide shares jumped 16.8% to $84.24 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) jumped 37.5% to $20.92 after the company reported better-than-expected first-quarter financial results.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 35.8% to $118.19 after the company announced upbeat quarterly results.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) surged 27.1% to $8.27 after the company reported mixed first-quarter financial results.</li>
<li>Gannett Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCI#NYSE">GCI</a>) rose 22.3% to $2.9519 following strong quarterly results.</li>
<li>Perdoceo Education Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) jumped 19.4% to $21.89 following upbeat results.</li>
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) rose 19.2% to $9.20 after the company reported better-than-expected first-quarter financial results.</li>
<li>Benchmark Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) surged 18.3% to $35.82 following better-than-expected quarterly results.</li>
<li>Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) rose 18% to $4.97 following strong quarterly results.</li>
<li>Rush Street Interactive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) shares gained 17.4% to $7.53 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) rose 15.7% to $109.62 after the company reported mixed first-quarter financial results.</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) climbed 15.2% to $76.93 after the company reported better-than-expected first-quarter financial results.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) rose 15% to $4.0399 after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>Valmont Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) rose 14.4% to $237.65 after the company posted upbeat quarterly earnings and raised FY24 EPS guidance.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) gained 13.7% to $107.81 after the company reported better-than-expected first-quarter results and raised FY24 revenue guidance.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) surged 12.8% to $76.09 after the company reported better-than-expected first-quarter results and raised its FY24 adjusted EPS outlook.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) climbed 12% to $72.08 after the company reported better-than-expected first-quarter EPS and sales.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) gained 11.7% to $56.53 after the company reported better-than-expected first-quarter financial results.</li>
<li>Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) rose 10.8% to $18.94 following strong sales.</li>
<li>Kontoor Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) gained 9.9% to $68.29 following better-than-expected quarterly results.</li>
<li>QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) climbed 8.5% to $178.02 after the company reported better-than-expected second-quarter financial results, raised its dividend and issued third-quarter guidance.</li>
<li>Belden Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) gained 8.2% to $87.95 after the company reported mixed first-quarter earnings and announced the acquisition of Precision Optical Technologies.</li>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) rose 8.1% to $61.60 following upbeat earnings.</li>
<li>Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) gained 7.7% to $106.55 following strong sales.</li>
<li>Sealed Air Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) surged 7.7% to $34.60 after the company reported better-than-expected quarterly financial results.</li>
<li>BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) gained 7.7% to $35.39 following upbeat earnings.</li>
<li>Itron, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) rose 7.4% to $98.39 following upbeat earnings.</li>
<li>IAC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) gained 6.8% to $51.11 after it was announced the stock will join the S&amp;P SmallCap 600.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares jumped 6.5% to $118.75 following first-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38584879/apple-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Apple Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Intraday Update

ASPN

BPMC

CHRW

CVNA

ENVX

ITRI

LNTH

LUNG

MRNA

NOVA

PRDO

QCOM

TROX

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $103 to $110.

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $110

Glaukos rises on upgrade to Buy at Jefferies

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genmab (GMAB – Research Report), Perspective Therape...

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)

Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK – Research Report), Glaukos (GK...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Glaukos (GKOS) and Arcus Biosciences (RCUS)

An update from Glaukos (GKOS) is now available. Glaukos Corporation's Board of Directors implemented the amended 2015 Omnibus Incentive Compensatio...

Glaukos Governance and Compensation Strategy Evolves

4 constructive medical devices stocks - BTIG

Glaukos cut as Citi reviews U.S. MedTechs

Glaukos cut as Citi reviews U.S. MedTechs ahead of Q2 results

Healthcare 2024 Second Half Outlook

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inozyme Pharma (INZY – Research Report), Glaukos (GK...

Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Glaukos (GKOS)

ALNY

AMGN

AZNCF

CATX

GEHC

GILD

GMAB

HALO

INZY

ISRG

MDEV

NONOF

NTRA

NVSEF

PLSE

PODD

PRCT

RCUS

RDNT

TMDX

TWST

VRTX

WGSWW

Press Releases

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Glaukos Announces the Release of its 2023 Sustainability Report

Glaukos Announces First Quarter 2024 Financial Results

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Glaukos

Glaukos (GKOS) Forecast

Glaukos (NYSE:GKOS) Stock, Quote.Headers.trade-ideas